CRDL vs. MOLN, VXRT, DBVT, SCLX, CRDF, BCAB, VIGL, OMGA, LIFE, and SGMO
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Molecular Partners (MOLN), Vaxart (VXRT), DBV Technologies (DBVT), Scilex (SCLX), Cardiff Oncology (CRDF), BioAtla (BCAB), Vigil Neuroscience (VIGL), Omega Therapeutics (OMGA), aTyr Pharma (LIFE), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
Cardiol Therapeutics (NASDAQ:CRDL) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Cardiol Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Molecular Partners' net margin of -885.11%. Molecular Partners' return on equity of -31.10% beat Cardiol Therapeutics' return on equity.
In the previous week, Cardiol Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Cardiol Therapeutics' score of 0.92 indicating that Molecular Partners is being referred to more favorably in the news media.
Cardiol Therapeutics received 3 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 50.00% of users gave Cardiol Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Cardiol Therapeutics has higher earnings, but lower revenue than Molecular Partners. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 180.37%. Molecular Partners has a consensus target price of $4.50, suggesting a potential upside of 18.42%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Molecular Partners.
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cardiol Therapeutics beats Molecular Partners on 11 of the 18 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
